Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 6/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1633685 | 0.98 | KIF11 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Phosphine SCHEMBL29270354 | 0.96 | KIF11 (0.52) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Bromide SCHEMBL9938231 | 0.94 | KIF11 (0.50) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL16468009 | 0.92 | KIF11 (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL19809495 | 0.86 | KIF11 (0.62) | KIF11NPSR1 | |
| SCHEMBL9874219 | 0.84 | KIF11 (0.55) | MAPTKIF11LMNAL3MBTL1TDP1 | |
| SCHEMBL5329346 | 0.84 | KIF11 (0.53) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11821408 | 0.83 | KIF11 (0.50) | MAPTKIF11LMNAL3MBTL1TDP1 | |
| SCHEMBL8046930 | 0.82 | HDAC6 (0.59) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL30806221 | 0.82 | KIF11 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916131-B2 | Radiopharmaceutical composition | GE HEALTHCARE LIMITED (GB) | 2014-12-23 | — | — | US | disclosed |
| US-20140303081-A1 | APOPTOSIS-TARGETING NANOPARTICLES | University of Georgia Foundation, Inc. (US) | 2014-10-09 | — | — | US | disclosed |
| US-7932290-B2 | Method for the treatment of metabolic disorders | WELLSTAT BIOLOGICS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100087541-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-7615575-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-7605181-B2 | Method for the treatment of metabolic disorders | Wellstat Therapeutics Orporation (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303081-A1 | APOPTOSIS-TARGETING NANOPARTICLES | AIFM1, BAX, BCL2 | HDAC3 2044/4885HDAC4 2788/4885HDAC1 1941/4885 |
| US-20100087541-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, CPT1A | HDAC3 152/4885HDAC4 1306/4885HDAC1 347/4885 |
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, CPT1A | HDAC3 152/4885HDAC4 1306/4885HDAC1 347/4885 |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | CPT1B, CPT1A, FABP1 | HDAC3 532/4885HDAC4 2096/4885HDAC1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.